References

  1. Scanlon ML, Vreeman RC. Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings. HIV AIDS. 2013;5:1-17. PubMed | Google Scholar

  2. Evans SR, Ellis RJ, Chen H, Yeh T, Lee AJ, Schifitto G et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS. 2011; 25(7): 919-28. PubMed | Google Scholar

  3. Keswani SC, Pardo CA, Cherry CL, Hoke A, McArthur JC. HIV-associated sensory neuropathies. AIDS. 2002; 16(16):2105-17. PubMed | Google Scholar

  4. Wulff EA, Wang AK, Simpson DM. HIV-associated peripheral neuropathy: epidemiology, pathophysiology, and treatment. Drugs. 2000;59(6):1251-60. PubMed | Google Scholar

  5. Kamerman PR, Wadley AL, Cherry CL. HIV-associated sensory neuropathy: Risk factors and genetics. Curr Opin Clin Nutr Metab Care. 2012 Jun;16(3):226-36. PubMed | Google Scholar

  6. National AIDS Control Council. Kenya AIDS Response Progress Report Progress towards Zero. Nascop, Minist Heal Gov Kenya. 2014; (March):37. PubMed | Google Scholar

  7. Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr. 2007; 45(3):304-10. PubMed | Google Scholar

  8. Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, Mermin J et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2007; 44(4): 456-62. PubMed | Google Scholar

  9. Maritz J, Benatar M, Dave JA, Harrison TB, Badri M, Levitt NS et al. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve. 2010;41(5): 599-606. PubMed | Google Scholar

  10. Cherry CL, Skolasky RL, Lal L, Creighton J, Hauer P, Raman SP et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology. 2006; 66(6):867-73. PubMed | Google Scholar

  11. Smyth K, Affandi JS, McArthur JC, Bowtell-Harris C, Mijch AM, Watson K et al. Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med. 2007;8(6):367-73. PubMed | Google Scholar

  12. Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, Shafer RW et al. Mitochondrial haplogroups, and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS. 2005;19(13):1341-9. PubMed | Google Scholar

  13. Quasney MW, Zhang Q, Sargent S, Mynatt M, Glass J, McArthur J. Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. Ann Neurol. 2001;50(2):157-62. PubMed | Google Scholar

  14. Price P, Morahan G, Huang D, Stone E, Cheong KYM, Castley A et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS. 2002;16(15):2043-7. PubMed | Google Scholar

  15. Maher B, Alfirevic A, Vilar FJ, Wilkins EGL, Park BK, Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS. 2002; 16(15):2013-8. PubMed | Google Scholar

  16. Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M et al. Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care. 2004;27(7):1591-7. PubMed | Google Scholar

  17. Sorensen L, Molyneaux L, Yue DK. Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity, and glycaemic control. Diabetes Res Clin Pract. 2002;57(1):45-51. PubMed | Google Scholar

  18. Gonzalez-Duarte A, Cikurel K, Simpson DM. Managing HIV peripheral neuropathy. Current HIV/AIDS Reports. 2007. p. 114-8. PubMed | Google Scholar

  19. Affandi JS, Price P, Imran D, Yunihastuti E, Djauzi S, Cherry CL. Can we predict neuropathy risk before stavudine prescription in a resource-limited setting?. AIDS Res Hum Retroviruses. 2008;24(10):1281-4. PubMed | Google Scholar

  20. Cherry CL, Affandi JS, Imran D, Yunihastuti E, Smyth K, Vanar S et al. Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology. 2009;73(4):315-20. PubMed | Google Scholar

  21. Wadley AL, Cherry CL, Price P, Kamerman PR. HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. J Pain Symptom Manage. 2011;41(4):700-6. PubMed | Google Scholar

  22. Mehta SA, Ahmed A, Laverty M, Holzman RS, Valentine F, Sivapalasingam S. Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy. Clin Infect Dis. 2011;53(5):490-6. PubMed | Google Scholar

  23. Tseng C-H. Prevalence of lower-extremity amputation among patients with diabetes mellitus: is height a factor?. CMAJ. 2006;174(3):319-23. PubMed | Google Scholar

  24. Cheng YJ, Gregg EW, Kahn HS, Williams DE, De Rekeneire N, Narayan KMV. Peripheral insensate neuropathy-A tall problem for US adults?. Am J Epidemiol. 2006;164(9):873-80. PubMed | Google Scholar

  25. Nyati LH, Norris SA, Cameron N, Pettifor JM. Effect of ethnicity and sex on the growth of the axial and appendicular skeleton of children living in a developing country. Am J Phys Anthropol. 2006;130(1):135-41. PubMed | Google Scholar

  26. Fowke KR, Nagelkerke NJ, Kimani J, Simonsen JN, Anzala AO, Bwayo JJ et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet. 1996;348(9038):1347-51. PubMed | Google Scholar

  27. World Health Organization. Physical status: the use and interpretation of anthropometry. Report of a WHO expert committee, WHO Technical Report Series 854, WHO, 1995; Geneva. Google Scholar

  28. World Health Organization. Antiretroviral therapy for HIV-1 infection in adults and adolescents. WHO, 2010; Geneva. Google Scholar

  29. World Health Organization. Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents. WHO, 2009; Geneva. Google Scholar

  30. Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010;67(5):552-8. PubMed | Google Scholar

  31. Luma HN, Tchaleu BCN, Doualla MS, Temfack E, Sopouassi VNK, Mapoure YN et al. HIV-associated sensory neuropathy in HIV-1 infected patients at the Douala General Hospital in Cameroon: a cross-sectional study. AIDS Res Ther. 2012;9(1):35. PubMed | Google Scholar

  32. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med. 1996;124(7):654-63. PubMed | Google Scholar

  33. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol. 2002; 8 Suppl 2:115-21. PubMed | Google Scholar

  34. Westreich DJ, Sanne I, Maskew M, Malope-Kgokong B, Conradie F, Majuba P et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis. 2009; 48(11):1617-23. PubMed | Google Scholar

  35. Cettomai D, Kwasa J, Kendi C, Birbeck GL, Price RW, Bukusi EA et al. Utility of quantitative sensory testing and screening tools in identifying HIV-associated peripheral neuropathy in Western Kenya: pilot testing. PLoS One. 2010; 5(12):e14256. PubMed | Google Scholar

  36. Mehta SA, Ahmed A, Kariuki BW, Said S, Omasete F, Mendillo M, et al. Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya. Am J Trop Med Hyg. 2010;83(3):565-70. PubMed | Google Scholar

  37. Evans D, Takuva S, Rassool M, Firnhaber C, Maskew M. Prevalence of peripheral neuropathy in antiretroviral therapy naive HIV-positive patients and the impact on treatment outcomes-a retrospective study from a large urban cohort in Johannesburg, South Africa. J Neurovirol. 2012;18(3):162-71. PubMed | Google Scholar

  38. Polydefkis M, Hauer P, Sheth S, Sirdofsky M, Griffin JW, McArthur JC. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain. 2004;127(Pt 7):1606-15. PubMed | Google Scholar

  39. Tumusiime DK, Venter F, Musenge E, Stewart A. Prevalence of peripheral neuropathy and its associated demographic and health status characteristics, among people on antiretroviral therapy in Rwanda. BioMed Central. 2014;14(1):1306. PubMed | Google Scholar

  40. Tumusiime DK, Musabeyezu E, Mutimurah E, Hoover DR, Shi Q, Rudakemwa E et al. Over-reported peripheral neuropathy symptoms in a cohort of HIV infected and uninfected Rwandan women: the need for validated locally appropriate questionnaires. Afr Health Sci. 2014;14(2):460-7. PubMed | Google Scholar

  41. Millogo A, Lankoandé D, Yameogo I, Yaméogo AA, Sawadogo AB. Polyneuropathies in patients treated with HAART in Bobo-Dioulasso hospital, Burkina Faso. Bull Soc Pathol Exot. 2008;101(1):11-3. PubMed | Google Scholar

  42. Mateo MG, Gutierrez M del M, Vidal F, Domingo P. Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS. Expert Opin Pharmacother. 2013;14(8):1055-64. PubMed | Google Scholar

  43. Banerjee S, McCutchan JA, Ances BM, Deutsch R, Riggs PK, Way L et al. Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy. AIDS. 2011;25(2):F1-6. PubMed | Google Scholar

  44. Moore RD, Wong WM, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine, and hydroxyurea. AIDS. 2000;14(3):273-8. PubMed | Google Scholar

  45. Breen RA, Lipman MC, Johnson MA. Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals. AIDS. 2000;14(5):615. PubMed | Google Scholar

  46. Cornblath DR, Hoke A. Recent advances in HIV neuropathy. Curr Opin Neurol. 2006;19(5):446-50. PubMed | Google Scholar

  47. Childs EA, Lyles RH, Selnes OA, Chen B, Miller EN, Cohen BA et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology. 1999;52(3):607-13. PubMed | Google Scholar

  48. Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol. 1999;56(1):84-9. PubMed | Google Scholar

  49. England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine and Am Neurology. 2009;72(2):185-92. PubMed | Google Scholar

  50. Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira D et al. Neuropathic pain: An updated grading system for research and clinical practice. Lancet Neurol. 2016;15(3):245. PubMed | Google Scholar